Having discovered BRCA2’s crucial role in genome stability, Professor Ashok Venkitaraman continues to drive research into cancer detection and treatment at the Cancer Science Institute of Singapore and A*STAR.
With a new classification scheme for angiosarcomas, health experts can develop and select more effective treatments for cancer patients.
The joint venture has resulted in the independent company JAGUAHR Therapeutics, which will focus on developing aryl hydrocarbon receptor antagonists for cancer treatment.
Tagrisso, a small molecule inhibitor drug, has been approved in China as a first-line treatment for patients with non-small cell lung tumors bearing specific mutations.
Singapore researchers have discovered that cancer stem cells consume the amino acid methionine much faster than it can be generated, and this vulnerability could be exploited for cancer treatment.